Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vanda Pharmaceuticals Inc. (VNDA : NSDQ)

• Company Description    Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. Number of Employees: 533

• Price / Volume Information    Yesterday's Closing Price: $5.43 Daily Weekly Monthly 20 Day Moving Average: 760,650 shares Shares Outstanding: 60.46 (millions) Market Capitalization: $328.31 (millions) Beta: 0.64 52 Week High: $9.94 52 Week Low: $4.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.17% 8.65% 12 Week -7.65% -9.62% Year To Date -38.44% -45.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 PENNSYLVANIA AVENUE NW SUITE 300E - WASHINGTON,DC 20037 USA ph: 202-734-3400 fax: 202-296-1450 pr@vandapharma.com http://www.vandapharma.com

• General Corporate Information    Officers Mihael H. Polymeropoulos - Chief Executive Officer; President and Chairman Kevin Moran - Chief Financial Officer and Senior Vice President Richard W. Dugan - Director Anne Sempowski Ward - Director Phaedra Chrousos - Director Peer Information Vanda Pharmaceuticals Inc. (CORR.) Vanda Pharmaceuticals Inc. (RSPI) Vanda Pharmaceuticals Inc. (CGXP) Vanda Pharmaceuticals Inc. (BGEN) Vanda Pharmaceuticals Inc. (GTBP) Vanda Pharmaceuticals Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 921659108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 60.46 Most Recent Split Date: (:1) Beta: 0.64 Market Capitalization: $328.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.49 Price/Cash Flow: - Price / Sales: 1.52 EPS Growth vs. Year Ago Period: -126.09% vs. Previous Quarter: -26.83% Sales Growth vs. Year Ago Period: -3.92% vs. Previous Quarter: -2.30% ROE 06/30/26 - -49.81 03/31/26 - -32.26 12/31/25 - -23.85 ROA 06/30/26 - -33.29 03/31/26 - -23.43 12/31/25 - -18.20 Current Ratio 06/30/26 - 1.61 03/31/26 - 2.16 12/31/25 - 2.39 Quick Ratio 06/30/26 - 1.60 03/31/26 - 2.15 12/31/25 - 2.38 Operating Margin 06/30/26 - -74.71 03/31/26 - -57.79 12/31/25 - -49.41 Net Margin 06/30/26 - -127.41 03/31/26 - -109.99 12/31/25 - -102.02 Pre-Tax Margin 06/30/26 - -82.14 03/31/26 - -68.74 12/31/25 - -64.16 Book Value 06/30/26 - 3.64 03/31/26 - 4.67 12/31/25 - 5.54 Inventory Turnover 06/30/26 - 7.43 03/31/26 - 6.54 12/31/25 - 6.53 Debt-to-Equity 06/30/26 - 0.01 03/31/26 - 0.01 12/31/25 - 0.01 Debt-to-Capital 06/30/26 - 1.42 03/31/26 - 1.33 12/31/25 - 1.23

Powered by Zacks Investment Research ©